'en:all-bfm-95 protocol'
(id=6934652 ; fe=en:all-bfm-95 protocol ; type=1 ; niveau=200 ;
luminosité=25 ;
somme entrante=658 creation date=2017-06-25 touchdate=2025-05-13 07:30:29.000) ≈ 12 relations sortantes
- en:all-bfm-95 protocol --
r_associated #0: 36 / 1 ->
en:daunorubicin
n1=en:all-bfm-95 protocol | n2=en:daunorubicin | rel=r_associated | relid=0 | w=36
- en:all-bfm-95 protocol --
r_associated #0: 35 / 0.972 ->
en:asparaginase
n1=en:all-bfm-95 protocol | n2=en:asparaginase | rel=r_associated | relid=0 | w=35
- en:all-bfm-95 protocol --
r_associated #0: 34 / 0.944 ->
en:antineoplastic combined chemotherapy protocols
n1=en:all-bfm-95 protocol | n2=en:antineoplastic combined chemotherapy protocols | rel=r_associated | relid=0 | w=34
- en:all-bfm-95 protocol --
r_associated #0: 32 / 0.889 ->
en:cyclophosphamide
n1=en:all-bfm-95 protocol | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=32
- en:all-bfm-95 protocol --
r_associated #0: 32 / 0.889 ->
en:vincristine
n1=en:all-bfm-95 protocol | n2=en:vincristine | rel=r_associated | relid=0 | w=32
- en:all-bfm-95 protocol --
r_associated #0: 28 / 0.778 ->
en:mercaptopurine
n1=en:all-bfm-95 protocol | n2=en:mercaptopurine | rel=r_associated | relid=0 | w=28
- en:all-bfm-95 protocol --
r_associated #0: 28 / 0.778 ->
en:prednisolone
n1=en:all-bfm-95 protocol | n2=en:prednisolone | rel=r_associated | relid=0 | w=28
- en:all-bfm-95 protocol --
r_associated #0: 26 / 0.722 ->
en:cytarabine
n1=en:all-bfm-95 protocol | n2=en:cytarabine | rel=r_associated | relid=0 | w=26
- en:all-bfm-95 protocol --
r_associated #0: 20 / 0.556 ->
asparaginase
n1=en:all-bfm-95 protocol | n2=asparaginase | rel=r_associated | relid=0 | w=20
- en:all-bfm-95 protocol --
r_associated #0: 20 / 0.556 ->
cyclophosphamide
n1=en:all-bfm-95 protocol | n2=cyclophosphamide | rel=r_associated | relid=0 | w=20
- en:all-bfm-95 protocol --
r_associated #0: 20 / 0.556 ->
daunorubicine
n1=en:all-bfm-95 protocol | n2=daunorubicine | rel=r_associated | relid=0 | w=20
- en:all-bfm-95 protocol --
r_associated #0: 3 / 0.083 ->
en:therapeutic or preventive procedure
n1=en:all-bfm-95 protocol | n2=en:therapeutic or preventive procedure | rel=r_associated | relid=0 | w=3
| ≈ 23 relations entrantes
- asparaginase ---
r_associated #0: 82 -->
en:all-bfm-95 protocol
n1=asparaginase | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=82
- en:asparaginase ---
r_associated #0: 79 -->
en:all-bfm-95 protocol
n1=en:asparaginase | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=79
- daunorubicine ---
r_associated #0: 75 -->
en:all-bfm-95 protocol
n1=daunorubicine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=75
- cyclophosphamide ---
r_associated #0: 71 -->
en:all-bfm-95 protocol
n1=cyclophosphamide | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=71
- en:daunorubicin ---
r_associated #0: 71 -->
en:all-bfm-95 protocol
n1=en:daunorubicin | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=71
- en:cyclophosphamide ---
r_associated #0: 67 -->
en:all-bfm-95 protocol
n1=en:cyclophosphamide | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=67
- en:antineoplastic combined chemotherapy protocols ---
r_associated #0: 20 -->
en:all-bfm-95 protocol
n1=en:antineoplastic combined chemotherapy protocols | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=20
- en:cytarabine ---
r_associated #0: 20 -->
en:all-bfm-95 protocol
n1=en:cytarabine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=20
- en:mercaptopurine ---
r_associated #0: 20 -->
en:all-bfm-95 protocol
n1=en:mercaptopurine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=20
- en:prednisolone ---
r_associated #0: 20 -->
en:all-bfm-95 protocol
n1=en:prednisolone | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=20
- en:vincristine ---
r_associated #0: 20 -->
en:all-bfm-95 protocol
n1=en:vincristine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=20
- cyclope (oeil) ---
r_associated #0: 15 -->
en:all-bfm-95 protocol
n1=cyclope (oeil) | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=15
- Asparaginase ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=Asparaginase | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- Cyclophosphamide ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=Cyclophosphamide | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- Daunorubicine ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=Daunorubicine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- cytarabine ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=cytarabine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- en:cyclops eye ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=en:cyclops eye | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- mercaptopurine ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=mercaptopurine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- prednisolone ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=prednisolone | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- vincristine ---
r_associated #0: 10 -->
en:all-bfm-95 protocol
n1=vincristine | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=10
- cyclopeptide ---
r_associated #0: 5 -->
en:all-bfm-95 protocol
n1=cyclopeptide | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=5
- cyclophiline ---
r_associated #0: 5 -->
en:all-bfm-95 protocol
n1=cyclophiline | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=5
- cyclophorie ---
r_associated #0: 5 -->
en:all-bfm-95 protocol
n1=cyclophorie | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=5
|